ClinicalTrials.gg
CompletedNCT06045364Updated Sep 5, 2024

Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation

A Phase 1/2 interventional study of Glycopyrrolate and Anisodamine in Nausea and Vomiting, sponsored by Jie Chen. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by Jie Chen · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Nausea with a site in China — 20 open to participants now, 20 under way, 9 of them phase 3. Nausea · China.

Enrollment
19th of 39
130 · median 122
Started
2023
with 2 others
Phase 1/2
Only one
of the 42
Registered
25th of 42
by date

Among the 42 studies in Nausea with a site in China, this one is the 19th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2023, is the only one in phase 1/2, and was the 25th registered.

Nausea

646 studies on the registry are indexed under Nausea; 87 are open to participants now.

Browse Nausea studies →

Open to participants now

20 of the 42 studies in Nausea with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 53 Nausea studies recruiting now, 23 (43%) set no upper age limit and 19 (36%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Nausea with a site in China, or all of them as a file.
02

Study summary

This study aims to determine the role of Glycopyrrolate in preventing postoperative nausea and vomiting of ERCP.

Read the detailed description

This study is a prospective, double-blind, randomized controlled trial. Patients who meet the criteria of our center and need to undergo ERCP lesion resection will be included and randomly divided into groups. After receiving Glycopyrrolate (experimental group) and Anisodamine (control group), duodenal peristalsis, biliary and pancreatic treatment time and postoperative nausea and vomiting will be observed during therapeutic ERCP. The inhibitory effect of Glycopyrrolate on postoperative nausea and vomiting of ERCP will be analyzed statistically.

Main outcome measure: incidence of nausea and vomiting after ERCP Secondary outcome measures: mean duodenal contractions per minute, duodenal spasm frequency and score, ERCP operation time, occurrence of other side effects of medication, remedial medication, and incidence of adverse events

03

Conditions studied

  • Nausea and Vomiting

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • 1.Adults 18-80 years old 2.ASA :I-III 3.Patients who are able to give and are currently planning to have the lesion removed or examined at the descending ERCP

Exclusion Criteria:1: Use of anticholinergic drugs

2: pregnancy

3: glaucoma

4: Myasthenia gravis

5: Obstructive gastrointestinal diseases

6: Obstructive urinary tract disease (prostatic hyperplasia)

7: Heart disease (coronary heart disease, congestive heart failure)

8: hyperthyroidism

9: Previous history of abdominal or intestinal surgery

10: Chronic renal failure

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    Glycopyrrolate

    During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously to participants.

    Drug: Glycopyrrolate

  • Active comparator
    Anisodamine Group

    During induction of anesthesia,10mg of Anisodamine was given intramuscular injection

    Drug: Anisodamine

Interventions

  • During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously

  • During induction of anesthesia,10mg of Anisodamine was given intramuscular injection.

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative nausea and vomiting

    Time frame: Timepoint:24 hours after the ERCP

07

Study locations

1 site
  • The Second Affiliated Hospital Of Chongqing Medical University
    Chongqing, Chongqing 400000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Jul 2024, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Sep 21, 2023
StartActual
Oct 1, 2023
Primary completionActual
Jul 20, 2024
CompletionActual
Jul 31, 2024
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06045364
Lead sponsor
Jie Chen
Responsible party
Jie Chen (Clinical Professor, The Second Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
Sep 21, 2023
Start date
Oct 1, 2023
Primary completion
Jul 20, 2024
Completion
Jul 31, 2024
Last update
Sep 5, 2024

Study contacts

Guangyou Duan, doctor
study director · The Second Affiliated Hospital of Chongqing Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion